Longeveron rises as Alzheimer's therapy succeeds in mid-stage study

Longeveron

05/10/2023 14:13

** Shares of cell therapy developer Longeveron Inc  LGVN.O 
rise 7.2% to $2.69 premarket   
    ** Co says its experimental therapy to treat mild
Alzheimer's disease met the main goal in a mid-stage study  
    ** The main goal was safety as measured by the occurrence of
serious adverse events within the first 30 days after each
administration of the therapy -LGVN
    ** The therapy, Lomecel-B, also showed lack of deterioration
in cognitive signals -LGVN 
    ** Lomecel-B is made from specialized cells isolated from
the bone marrow of young healthy adult donors which are
essential for the body's biological repair mechanism 
     ** Co plans to announce additional data from this trial
later this month
    ** Up to last close, stock down ~22% YTD  

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))